对于患有晚期充血性心力衰竭和左心室缩功能下降的患者,Qt分散没有预后信息
1Copenhagen University Hospital, Gentofte, Denmark.
Circulation
|February 15, 2001
概括
QT分散不能预测晚期充血性心力衰竭 (CHF) 患者的死亡率. 这项研究没有发现QT分散与心脏病患者的任何原因,心脏病或心律失常死亡之间的联系.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 心脏衰竭研究研究
背景情况:
- QT分散是动脉节律事件和死亡率的潜在预后标志物.
- 它在患有充血性心力衰竭 (CHF) 的患者的预后价值仍然不清楚.
研究的目的:
- 为了研究QT分散的预后价值,在患有晚期慢性心脏病和左心室功能障碍的患者中.
主要方法:
- 在Diamond-CHF研究中分析了703名晚期心血管衰竭患者的基线心电图.
- 随访时间中位数为18个月,评估所有原因,心脏和心律失常死亡率.
- 生存分析以确定从QT分散得出的预后信息.
主要成果:
- 中位数QT分散为70毫秒,幸存者和非幸存者之间没有显著差异.
- QT分散没有显示所有原因死亡率的预后值 (P=0.74).
- QT分散没有预测心脏死亡率 (P=0.55) 或心律失常死亡率 (P=0.38).
结论:
- 在患有晚期慢性心血管衰竭和左心室缩功能下降的患者中,QT分散缺乏对死亡结果的预后价值.
相关概念视频
Cardiomyopathy II: Dilated Cardiomyopathy
107
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
107
Heart Failure VI: Adjunct Therapies
68
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
68
Heart Failure V: Medical Management
60
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
60
Heart Failure IV: Classification and Diagnostic Evaluation
93
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
93
Mitral Stenosis II: Clinical features and Diagnostic Tests
61
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
61
Heart Failure Drugs: Diuretics
575
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
575


